臨床婦人科産科72巻6号

2018年06月発行

今月の臨床 がん免疫療法の新展開─「知らない」ではすまない今のトレンド がん免疫療法の応用と問題点─婦人科腫瘍を中心に

免疫療法にはどのような問題点・副作用があるか？

著者： 河野光一郎¹ 牛嶋公生¹

所属機関： ¹久留米大学医学部産婦人科学講座

ページ範囲：P.584 - P.591

●がん免疫療法では一時的に病勢が進行もしくはそのようにみえることもあるため，効果判定時には考慮が必要である．

●治療効果を予測するバイオマーカーとしてmutation burden，腫瘍浸潤リンパ球，PD-L1発現が有望であり，今後の研究に期待したい．

●これまでの薬物療法と異なる免疫療法特有な有害事象があること，発症が急で一部では致死的になることもあるため，注意深い観察と各専門医との連携体制を構築しておくことが重要である．

参考文献

1）Robert C, et al : Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 : 2521─2532, 2015

2）Weber JS, et al : Nivolumab versus chemotherapy in patients with advance melanoma who progressed after anti-CTLA-4 treatment（CheckMate 037） : a randomized, controlled, open-label, phase 3 trial. Lancet Oncol 16 : 375─384, 2015

3）Larkin J, et al : Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 : 23─34, 2015

4）Hamanishi J, et al : Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33 : 4015─4022, 2015

5）Morgan RA, et al : Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 : 126─129, 2006

6）Maude SL, et al : Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 37 : 1507─1517, 2014

7）Small EJ, et al : Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T（APC8015）in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24 : 3089─3094, 2006

8）Wolchok JD, et al : Guidelines for the evaluation of immune therapy activity in solid tumors ; immune-related response criteria. Clin Cancer Res 15 : 7412─7420, 2009

9）Bohnsack O, et al : Adaptation of the immune related response criteria : irRECIST. Ann Oncol 25（Supple 4）: 361─372, 2014

10）Seymour L, et al : iRECIST : guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18 : 143─152, 2017

11）Topalian SL, et al : Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32 : 1020─1030, 2014

12）Garon E, et al : Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 373 : 2018─2028, 2015

13）Brahmer JR, et al : Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 : 123─135, 2015

14）Borghaei H, et al : Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 : 1627─1639, 2015

15）Motzer RJ, et al : Nivolumab for metastatic renal cell carcinoma : results of a randomized phase II trial. J Clin Oncol 33 : 1430─1437, 2015

16）Motzer RJ, et al : Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 : 1803─1813, 2015

17）Topalian SL, et al : Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16 : 275─287, 2016

18）Gibney GT, et al : Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 16 : 542─551, 2016

19）Dudley JC, et al : Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 22 : 813─820, 2016

20）Le DT, et al : PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 : 2509─2520, 2015

21）Zighelboim I, et al : Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of endometrioid type. J Clin Oncol 25 : 2042─2048, 2007

22）Hampel H, et al : Screening for Lynch syndrome（hereditary nonpolyposis colorectal cancer）among endometrial cancer patients. Cancer Res 66 : 7810─7817, 2006

23）Murphy MA, et al : Frequency of mismatch repair deficiency in ovarian cancer : a systematic review This article is a US government work and, as such, is in the public domain of the United States of America. Int J Cancer 129 : 1914─1922, 2011

24）Howitt BE, et al : Clear cell ovarian cancers with microsatellite instability : unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. Oncoimmunology 6 : e1277308, 2017

25）Garguilo P, et al : Tumor genotype and immune environment in POLE-ultramutated and MSI-hypermutated endometrial cancers : new candidates for checkpoint blockade immunotherapy? Cancer Treat Rev 48 : 61─68, 2016

26）Kyle C, et al : Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 7 : 13587─13598, 2016

27）Haanen JB, et al : Toxicity patterns with immunomodulating antibodies and their combinations. Semin Oncol 42 : 423─428, 2015

28）Hassel JC, et al : Combined immune checkpoint blockade（anti-PD-1/anti-CTLA-4）: Evaluation and management of adverse drug reactions. Cancer Treat Rev 57 : 36─49, 2017

29）Weber JS, et al : Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30 : 2691─2697, 2012

30）Harding JJ, et al : Vemurafenib sensitivity skin reaction after ipilimumab. N Engl J Med 366 : 373─377, 2012

31）Spain L, et al : Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44 : 51─60, 2016

32）Albarel F, et al : Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol 172 : 195─204, 2015

33）Koelzer VH, et al : Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors -an autopsy study. J Immunother Cancer 4 : 13, 2016

34）Nishino M, et al : Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 373 : 288─290, 2015

35）Wilgenhof S, et al : Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol 22 : 991─993, 2011

36）Johnson DB, et al : Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol 33 : 122─124, 2015

37）Neelapu SS, et al : Chimeric antigen receptor T-cell therapy -assessment and management of toxicities. Nat Rev Clin Oncol 15 : 47─62, 2018

38）Grupp SA, et al : Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368 : 1509─1518, 2006

39）Morgan RA, et al : Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36 : 133─151, 2013

40）Cameron BJ, et al : Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med 5 : 197ra103, 2013